Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer
about
ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsOverall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysis of clinical trials.Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung CancerAssociation between the histological subtype of lung adenocarcinoma, EGFR/KRAS mutation status and the ALK rearrangement according to the novel IASLC/ATS/ERS classification.Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung CancerClinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
P2860
Q26820845-44FE431E-C000-40FE-AEBC-2F00B3F54E7DQ33591738-91B26D8B-9910-42A8-9F98-719843614DC4Q34268266-B58E9585-3728-4AD6-9E88-92281EB3B936Q35812568-CC63A4C5-342E-46EB-9567-C42EBAEE2CD0Q36741152-154E6FC5-131E-4814-9445-0E6D81BD475BQ37298872-8C472E95-B585-486F-A75D-4045BFA4F400Q38241120-44CC9D95-E76A-446D-A638-401EFF03F9A1Q38266308-0A39345D-E6C1-4E15-9628-791E079B56E0Q38669285-A6428F27-FF51-4374-99EB-69C6D74B6790Q39027385-348B1B3C-E904-401D-8E4D-361E11FD4212Q41043819-E8E2332C-ADCE-46B0-A64F-8067AF9989F9Q47303076-19B3EB9C-DB14-4A85-A058-B042C3482EC7Q50045235-7CAB8791-BB24-43A8-82CA-4631ABBF2E62
P2860
Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@ast
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@en
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@nl
type
label
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@ast
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@en
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@nl
prefLabel
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@ast
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@en
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@nl
P2093
P2860
P1433
P1476
Clinical benefit from pemetrex ...... ive non-small-cell lung cancer
@en
P2093
Anna E Barón
Benjamin J Solomon
D Ross Camidge
Delee Maxson
Eamon M Berge
Maria Varella-Garcia
Robert C Doebele
Shirish M Gadgeel
P2860
P304
P356
10.1016/J.CLLC.2013.06.005
P407
P577
2013-08-06T00:00:00Z